[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367758-105":59,"doc-detail-367758-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","association-between-ercc2-lys751gln-asp312asn-and-arg156arg-polymorphisms-and-gynecological-cancer-susceptibility-a-meta-analysis","Association between ERCC2 Lys751Gln, Asp312Asn, and Arg156Arg polymorphisms and gynecological cancer susceptibility: a meta-analysis","","Systematic review and meta-analysis evaluated whether ERCC2 Lys751Gln, Asp312Asn, and Arg156Arg polymorphisms influence susceptibility to gynecological tumors. Case-control studies were searched in PubMed, Cochrane Library, Embase, and Web of Science up to October 2024, and pooled odds ratios with 95% confidence intervals were calculated using Stata 17. Nineteen studies (9433 cases, 13144 controls) were included. Lys751Gln increased gynecologic neoplasm risk, especially for ovarian cancer, while Asp312Asn showed no overall risk elevation and may protect against cervical cancer. Arg156Arg was not associated with susceptibility.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/association-between-ercc2-lys751gln-asp312asn-and-arg156arg-polymorphisms-and-gynecological-cancer-susceptibility-a-meta-analysis/367758/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/association-between-ercc2-lys751gln-asp312asn-and-arg156arg-polymorphisms-and-gynecological-cancer-susceptibility-a-meta-analysis/367758.png","ImageObject",300,407,{"name":92,"@type":93},"Mabel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What did the meta-analysis investigate about ERCC2 polymorphisms?","Question",{"text":112,"@type":113},"It assessed whether ERCC2 Lys751Gln, Asp312Asn, and Arg156Arg polymorphisms are associated with gynecological cancer susceptibility.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which ERCC2 variant was linked to increased gynecological cancer risk?",{"text":117,"@type":113},"The ERCC2 Lys751Gln polymorphism was associated with increased risk of gynecologic neoplasms, with a specific association observed for ovarian cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"Were Asp312Asn and Arg156Arg associated with gynecological cancer susceptibility?",{"text":121,"@type":113},"Asp312Asn did not elevate overall risk; the recessive model suggested a protective effect for cervical cancer. Arg156Arg showed no association with susceptibility.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367758,1790200180,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","TYPE Systematic Review PUBLISHED 24 July 2025  \nDOI 10.3389/fonc.2025.1461015  \nOPEN ACCESS  \nEDITED BY  \nRobert Fruscio,  \nUniversity of Milano Bicocca, Italy  \nREVIEWED BY  \nSandhya Annamaneni, Osmania University, India Tasaduq H. Wani,  \nUniversity of Oxford, United Kingdom  \n*CORRESPONDENCE  \nChun-Guang Wang  \n [1783084236@qq.com](1783084236@qq.com)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 07 July 2024  \nACCEPTED 12 June 2025  \nPUBLISHED 24 July 2025  \nCORRECTED 25 September 2025  \nCITATION  \nChen F, Yu J and Wang C-G (2025)  \nAssociation between ERCC2  \nLys751Gln, Asp312Asn, and Arg156Arg polymorphisms and gynecological cancer susceptibility: a meta-analysis.  \nFront. Oncol. 15:1461015 .  \ndoi: 10.3389/fonc.2025.1461015  \nCOPYRIGHT  \n© 2025 Chen, Yu and Wang. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAssociation between ERCC2 Lys751Gln, Asp312Asn, and Arg156Arg polymorphismsand gynecological cancer susceptibility: a meta-analysis  \nFen Chen †, Jiayang Yu † and Chun-Guang Wang*  \nDepartment of Oncology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China  \nBackground: Gynecological tumors are diseases that pose serious threats to women ’s health. Cervical, endometrial, and ovarian cancers are the most common gynecologic tumors. Excision repair cross-complementation group 2 (ERCC2) plays a critical role in nucleotide excision repair. Polymorphisms in ERCC2 can inﬂuence DNA damage repair mechanisms, potentially increasing susceptibility to tumors. However, several studies have investigated the association between ERCC2 polymorphisms and the risk of gynecological tumors, but the results have been inconsistent. Therefore, we performed this meta-analysis to estimate these associations more precisely.  \nObject: In this paper, we summarized a larger sample for meta-analysis to explored the relationship between the polymorphisms of the ERCC2 Lys751Gln, Asp312Asn, and Arg156Arg and gynecological tumors.  \nMethods: We conducted a systematic search for relevant case-control studies in PubMed, the Cochrane Library, Embase, and the Web of Science databases, covering studies up to October 2024 . The odds ratio (OR) and its 95% conﬁdence interval (CI) were calculated using Stata 17 software.  \nResults: Finally, a total of 19 studies (9433 cases and 13144 controls) were included. 17 studies (3742 cases and 5591 controls) were conducted on the Lys751Gln polymorphism. Additionally, 9 studies(2,170 cases and 3,582 controls) were available for the Asp312Asn polymorphism, while 8 studies (3,521 cases and 3,971 controls)were included for the Arg156Arg polymorphism. Of these, 16 focused on ovarian cancer, 8 on cervical cancer, and 10 on endometrial cancer. The ERCC2 Lys751Gln polymorphism was found to increase the risk of gynecologic neoplasms(C vs A:OR 1.33, 95% CI 1.06-1.66;CC+CA vs AA:OR 1.33, 95% CI 1 .11-1. 59) . Subgroup analysis by cancer type indicated an association of the Lys751Gln polymorphism with the development of ovarian cancer (CC+CA vs AA:OR 1.39, 95% CI 1.04-1.86), while no signiﬁcant correlation was observed with cervical and endometrial cancers. Further subgroup analyses revealed that the Lys751Gln polymorphism increased the risk of gynecologic neoplasms in Caucasian and African populations, as well as in hospital-based studies. In contrast, the ERCC2 Asp312Asn polymorphism did not elevate the risk of gynecologic neoplasms, and the recessive gene variant was even protective against cervical cancer (AA vs GA+GG : OR 0 . 53, 95%CI 0 .34-0. 83, P=0 . 005) .  \nF","cbCaijvG9nSTkM4H","https://ap.wps.com/l/cbCaijvG9nSTkM4H","pdf",8175304,15,"English","# Background\n# Objective\n# Methods\n# Results\n## Lys751Gln findings\n## Asp312Asn findings\n## Arg156Arg findings\n## Subgroup analyses\n# Conclusion","[{\"question\":\"What did the meta-analysis investigate about ERCC2 polymorphisms?\",\"answer\":\"It assessed whether ERCC2 Lys751Gln, Asp312Asn, and Arg156Arg polymorphisms are associated with gynecological cancer susceptibility.\"},{\"question\":\"Which ERCC2 variant was linked to increased gynecological cancer risk?\",\"answer\":\"The ERCC2 Lys751Gln polymorphism was associated with increased risk of gynecologic neoplasms, with a specific association observed for ovarian cancer.\"},{\"question\":\"Were Asp312Asn and Arg156Arg associated with gynecological cancer susceptibility?\",\"answer\":\"Asp312Asn did not elevate overall risk; the recessive model suggested a protective effect for cervical cancer. Arg156Arg showed no association with susceptibility.\"}]","Association between ERCC2 Lys751Gln, Asp312Asn, and Arg156Arg polymorphisms and gynecological cancer susceptibility: a meta-analysis | PDF",1790172448,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0e7171cfbb5cc14297a2ab32979848d.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4764f6e10e14b3b273f26a1de38e03b5.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47fd0c20b8870b9b9736fab54b50cea2.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f68fd35eaaf1cd5559c4be54d67b94b.webp",980,1385]